Released May 4, 2023, before the open
10-Q filed May 4, 2023, 34 days after period end · 0001558370-23-008132
Q1 2023 · 10-Q
Revenue$9.59M$9.59M −40.4% vs Q1 2022+11.3% vs Q4 2022
Net Income-$3.13M-$3.13M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.05-$0.05 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$2,459,000N/M
Operating Cash Flow-$2,998,000N/M
Free Cash Flowderived-$3,246,000N/M
Margins · derived
Operating margin-25.6%−14.0 pt vs Q1 2022
Net margin-32.7%−18.4 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $9.59M | $16.09M | $11.32M | $21.65M |
| Net Income | -$3.13M | -$2.29M | -$5.48M | $1.67M |
| EPS Diluted | -$0.05 | -$0.05 | -$0.14 | $0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR